When was Ambys Medicines founded?

Ambys Medicines was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Ambys Medicines located?

Ambys Medicines is headquartered in Redwood City, United States.

How many employees does Ambys Medicines have?

As of Jul 01, 2024, the latest employee count at Ambys Medicines is 77.

Is Ambys Medicines a funded company?

Ambys Medicines is a funded company, having raised a total of $107M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 08, 2018.

When was the latest funding round of Ambys Medicines?

Ambys Medicines' latest funding was a $***** Series A round on Dec 21, 2021, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $455M in funding in 2026 to date.

Where does Ambys Medicines rank among its competitors?

Ambys Medicines ranks 157th amongst 651 active competitors, of which 235 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Ambys Medicines?

Ambys Medicines' top competitors include Spark Therapeutics, Sana Biotechnology and Ultragenyx. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Ambys Medicines - 2026 Company Profile, Team, Funding & Competitors

Ambys Medicines is a series A company based in Redwood City (United States), founded in 2018 by Holger Willenbring, Juan Belmonte, Markus Grompe and Martin Burke. It operates as a Developer of cell therapies to treat severe liver diseases. Ambys Medicines has raised $107M in funding from Third Rock Ventures and Takeda. The company has 651 active competitors, including 235 funded and 168 that have exited. Its top competitors include companies like Spark Therapeutics, Sana Biotechnology and Ultragenyx.

Company Details

Developer of cell therapies to treat severe liver diseases. The company is pioneering the novel application of cell therapies to restore and reverse liver disease progression. The lead candidate AMI-918, a hepatocyte replacement cell therapy, harness the natural regenerative properties of the liver and target a spectrum of severe acute and chronic liver diseases to restore normal liver function.

Website: www.ambys.com/
Social
Email ID: *****@ambys.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2018

Location

Redwood City, United States

Stage

Series A

Total Funding

$107M in 2 rounds

Latest Funding Round

Series A, Dec 21, 2021, $*****

Investors

Third Rock Ventures & 5 more

Ranked

157^th among 651 active competitors

Employee Count

77 as on Jul 01, 2024

Similar Companies

Spark Therapeutics & 746 more

View Ambys Medicines' full profile

Ambys Medicines has raised a total funding of $107M over 2 rounds. Its first funding round was on Aug 08, 2018. Its latest funding round was a Series A round on Dec 21, 2021 for $*****. 6 investors participated in its latest round. Ambys Medicines has 6 institutional investors.

Here is the list of recent funding rounds of Ambys Medicines:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 21, 2021	3593363	Series A	8610608	3496895	3674524	1002224
Aug 08, 2018	1362687	Series A	1322361	9830612	Third Rock Ventures & 1 more	8483191

Access funding benchmarks and valuations. Sign up today!

View details of Ambys Medicines's funding rounds and investors

The founders of Ambys Medicines are Holger Willenbring, Juan Belmonte, Markus Grompe and Martin Burke.

Here are the details of Ambys Medicines' key team members:

Holger Willenbring: managing director of Ambys Medicines.
Juan Belmonte: Co-Founder of Ambys Medicines.
Markus Grompe: Scientific Founder of Ambys Medicines.
Martin Burke: Professor of Ambys Medicines.

View details of Ambys Medicines's Founder profiles and Board Members

Ambys Medicines' employee count trend

Ambys Medicines has 77 employees as of Jul 24. Here is Ambys Medicines's employee count trend over the years:

Employee count trend for Ambys Medicines

Uncover Ambys Medicines' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ambys Medicines include Spark Therapeutics, Sana Biotechnology and Ultragenyx. Here is the list of Top 10 competitors of Ambys Medicines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	76/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	71/100
4th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
5th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
7th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
8th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Healthcare Partners, Frazier Life Sciences ... & 2 others	69/100
157th	Ambys Medicines 2018, Redwood City (United States), Series A	Developer of cell therapies to treat severe liver diseases	$107M	Laurion Capital, Alexandria & 4 others	50/100